Navigation Links
Abbott 'Goes Red' to Educate Bay Area Women About Heart Disease
Date:2/1/2008

Abbott Sponsors American Heart Association's 'Go Red for Women' Movement in

the Bay Area

SANTA CLARA, Calif., Feb. 1 /PRNewswire/ -- As a leader in cardiovascular treatment and the exclusive Bay Area "hometown" partner for the national "Go Red for Women" program, Abbott (http://www.abbott.com) is partnering with the American Heart Association (AHA) to raise awareness about heart disease, the leading cause of death for women in America.

One out of every three American women will die of heart disease, yet, according to AHA, only 13 percent of women believe heart disease is their greatest health risk. While largely preventable, heart disease in women often goes underdiagnosed and undertreated. Data shows that most women fail to make the connection between risk factors like high blood pressure and high cholesterol and their risk of developing heart disease.

Through this year-long campaign, which kicks off in February -- American Heart Month -- Abbott and AHA hope to raise awareness that even women without classic risk factors and symptoms may be at risk -- just ask Michelle Smietana, a software testing engineer at Abbott. Ironically, Michelle just had her blood pressure and cholesterol checked -- both were normal. While she used to smoke and had been a bit overweight, she was feeling strong and healthy so she didn't know what to suspect last spring when she experienced some back pain that crept into her neck. At just 33, both she and the cardiologist who treated her were shocked when her ultrasound results showed evidence of a heart attack.

"If heart disease can happen to me, it can happen to anyone. I was only

33, had low cholesterol and good blood pressure. I didn't have the

"normal" symptoms you associate with heart disease like left arm pain and

pressure in my chest. Going through cardiac rehabilitation helped make

exer
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Abbott to Present at Merrill Lynch Healthcare Conference
2. Abbotts Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
3. Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2007 Earnings
4. Cookie Johnson and Abbott Bring I Stand With Magic: Campaign to End Black AIDS to Los Angeles to Educate African-American Women on HIV/AIDS
5. Ugandan Children Are Among the First to Receive Abbotts Lower-Strength Aluvia (lopinavir/ritonavir) Tablet
6. The Magic Johnson Foundation and Abbott Expand Focus of Campaign to End Black AIDS to African-American Women in 2008
7. FDA Advisory Committee Recommends Approval of Abbotts XIENCE(TM) V Drug Eluting Stent System
8. Abbotts Environmental Protection Initiatives Again Recognized by the State of Illinois
9. Abbott Employees Give Back to Local Communities This Holiday Season
10. AUDIO from Medialink and Abbott Labs: Easing Holiday Stress for Families of Those With Diabetes
11. Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... a new study done from the heights of Mount ... increases if you ascend to great heights. They ... high blood pressure was ineffective once climbers reached above ... 27 in the European Heart Journal , could ... level who have sleep apnea, in which a blocked ...
(Date:8/27/2014)... 2014 BESLER Consulting , a ... for hospitals, is pleased to announce that it has ... America’s Fastest-Growing Companies. The list represents the most comprehensive ... entrepreneurs. , "It's been an exciting year for ... in this year's Inc. 5000 list,” said Jonathan Besler, ...
(Date:8/27/2014)... The American Brain Tumor Association ... Basic Research Fellowships and 2014-2015 Discovery Grant Awards. Through ... seeding the field with talented, bright young investigators who ... causes, effects, diagnosis and treatment of brain tumors. This ... on the potential to advance the understanding and treatment ...
(Date:8/27/2014)... drug designed to help regulate the blood,s iron supply shows ... according to results from the first human study ... , the Journal of the American Society of ... red blood cells are in short supply or do not ... not get enough oxygen, since there are fewer red blood ...
(Date:8/27/2014)... A new analysis of clinical trial participation in the ... has found participants are not representative of the larger ... College Hospital cardiologist Dr. Jay Udell. The study authors ... to the wider population, and suggest the use of ... trial participation. , "We know that clinical trials can ...
Breaking Medicine News(10 mins):Health News:Everest Study Finds High Altitude Affects Blood Pressure 2Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Drug represents first potential treatment for common anemia 2Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2
... a combination of treatments tailor-made to their specific needs to ... immune response to cancer vaccines, because like the rest of ... efficient as we get older. Dr. Joseph Lustgarten, from the ... effects of aging on the immune system and strategies used ...
... are justified, say hearing loss experts who urge prevention , ... typically long -- and get longer when their children become ... about hearing loss. , Parents, in fact, worry more about ... health-related issues, including ear infections, sleep problems and asthma, according ...
... Greater Surface Disinfection to Combat Bad Hygiene , ARLINGTON, Va., ... standing in the lunch line? Or sneeze loudly into the ... (96 percent) have seen you do things like this -- and ... , Even with heightened concerns during this year,s flu season, ...
... , ... on the forefront of adopting social media outlets for physician recruitment , ... Alpharetta, GA (Vocus) October 8, 2009 -- "Jackson ... aspects of physician recruitment and other company functions," says company president, Sandra Garrett., , , ...
... ... malignancy after using a new treatment offered by NeoPlas Innovation. , ... Nashville, Tenn. (PRWEB) October 7, 2009 -- A patient ... after using a new treatment offered by NeoPlas Innovation . All evidence of disease ...
... Bipartisan Policy Center,s Health Care Report Urge Joint Leadership on ... is a statement released by Bipartisan Policy Center Founders and ... Bob Dole: , "After 14 months of work, on June ... It was the culmination of months of work as advisors ...
Cached Medicine News:Health News:Elderly immune system needs a boost 2Health News:As Teens Plug In, Parents Fret 2Health News:As Teens Plug In, Parents Fret 3Health News:Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns 2Health News:Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns 3Health News:Jackson & Coker Investigates the Impact of Social Media on Hospitals and Physicians 2Health News:Jackson & Coker Investigates the Impact of Social Media on Hospitals and Physicians 3Health News:Jackson & Coker Investigates the Impact of Social Media on Hospitals and Physicians 4Health News:Jackson & Coker Investigates the Impact of Social Media on Hospitals and Physicians 5Health News:Inoperable Colon Cancer Resolved After Four Months of New Treatment 2Health News:Inoperable Colon Cancer Resolved After Four Months of New Treatment 3
(Date:8/27/2014)... Aug. 27, 2014  Columbia Laboratories, Inc. (Nasdaq: ... of pharmaceutical development, clinical trial manufacturing, and advanced analytical ... that it will participate at the upcoming Rodman & ... be held in New York . ... on September 9, 2014 at the New York Palace ...
(Date:8/27/2014)... NORWALK, Conn. , Aug. 27, 2014  UBM ... , a leading online community for medical imaging professionals, ... Association for Medical Imaging Management,s 2014 Annual Meeting ... the conference coverage: , 11 Principles ... management can lead to greater profitability. , ...
(Date:8/27/2014)... DIEGO , Aug. 27, 2014 Ambit Biosciences (Nasdaq: ... and development of drugs targeting unmet needs in oncology, autoimmune ... Baird 2014 Health Care Conference to be held at The ... on September 3-4, 2014. Alan ... Company and its lead drug candidate, quizartinib, at 1:10 p.m. ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Ambit Announces Participation At Baird 2014 Health Care Conference 2
... Oramed Pharmaceuticals, Inc.,(OTCBB: ORMP.OB) ( http://www.oramed.com ), a ... to present at the 8th National Life,Science & Technology ... by Mr. Nadav Kidron, President and CEO of Oramed,on ... p.m. (local time),at the David Intercontinental Hotel in Tel-Aviv, ...
... Patients Demonstrated Improvement With Every-Four-Week Subcutaneous SIMPONI Despite ... , COPENHAGEN, June 9 A new analysis ... moderately to severely active rheumatoid arthritis (RA) who ... agents and received subcutaneous injections of SIMPONI(TM) (golimumab) ...
Cached Medicine Technology:Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 3New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 4New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 5New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 6New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 7New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 8New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 9New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 10
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: